Leukemia, Myeloid: all 2,432 studies
Page 13 of 25. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I TrialTerminatedNCT03735446Phase 1
- Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive ChemotherapyCompletedNCT03728699
- Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT03723681Phase 1
- Expanded Access for CC-486Approved for marketingNCT03723135
- A Study of Perpetrator Drug Interactions of Enasidenib in AML PatientsCompletedNCT03720366Phase 1
- Haplo HCT vs Haplo-cord HCT for Patients With AMLCompletedNCT03719534Phase 3
- Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AMLCompletedNCT03719183
- Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCTStatus unknownNCT03715621
- Actinium-225-Lintuzumab in Patients With Acute Myeloid LeukemiaWithdrawnNCT03705858Phase 1
- Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AMLStatus unknownNCT03701217Phase 2/3
- Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)WithdrawnNCT03699384Phase 1/2
- Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid LeukaemiaActive, not recruitingNCT03697707Phase 2
- IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCTTerminatedNCT03696537Phase 1
- A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AMLTerminatedNCT03690154Phase 1
- Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML PatientsCompletedNCT03690115Phase 2
- Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.CompletedNCT03672695Phase 1
- The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AMLStatus unknownNCT03665480Phase 2/3
- Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AMLCompletedNCT03661515Phase 1
- Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT03659084
- CALLS: CML and Ph+ALL Low Level Mutation Prevalence SurveyCompletedNCT03647215
- Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AMLStatus unknownNCT03642236Phase 2/3
- The Hong Kong CML RegistryStatus unknownNCT03625583
- A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03625505Phase 1
- Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaCompletedNCT03625388Phase 2
- Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT03616470Phase 3
- Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)Active, not recruitingNCT03609060Phase 2
- Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction ChemotherapyActive, not recruitingNCT03603795Phase 2
- Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationWithdrawnNCT03602898Phase 2
- Efficacy of FLAG Regimen for the Treatment of Patients With AMLStatus unknownNCT03600558
- COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeActive, not recruitingNCT03595787Not applicable
- NGS in AML RelapseStatus unknownNCT03582241
- Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)CompletedNCT03564288Phase 1
- A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid LeukemiaCompletedNCT03563560Phase 1
- The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative NeoplasmStatus unknownNCT03558607Phase 1/2
- CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）Status unknownNCT03556982Phase 1/2
- Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for SurvivalTerminatedNCT03549351
- Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov ApproachCompletedNCT03540654
- Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AMLCompletedNCT03537560
- Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCTStatus unknownNCT03530085Phase 2/3
- A Post-Marketing Observational Study of VYXEOS™CompletedNCT03526926
- Ascorbic Acid Levels in MDS, AML, and CMML PatientsCompletedNCT03526666
- EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute LeukemiaTerminatedNCT03519984Phase 1
- Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid LeukemiaTerminatedNCT03516760Phase 1
- Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid LeukemiaWithdrawnNCT03515707Phase 2
- Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)CompletedNCT03509896
- Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted TherapyStatus unknownNCT03499912
- Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486CompletedNCT03493646Phase 2
- Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML PatientsCompletedNCT03488862
- A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT03484520Phase 1
- Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid LeukemiaTerminatedNCT03483948Phase 1
- CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT03473457Not applicable
- Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDSCompletedNCT03459859Phase 1
- Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic LeukemiaCompletedNCT03455517Phase 2
- Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in EgyptCompletedNCT03454503
- Immune Checkpoint Receptors in AML-Leukemic Initiating CellsCompletedNCT03449745
- AML Electronic Decision AidCompletedNCT03442452Not applicable
- A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03441555Phase 1
- Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03441048Phase 1
- Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell TransplantWithdrawnNCT03438344Phase 2
- Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction TherapyCompletedNCT03435848Phase 2
- Survival in Patients Older Than 60 Years With Newly Diagnosed AML in SpainCompletedNCT03435341
- Observational Study of Spatio-Temporal Patterns of New Cases of Acute Myeloid LeukemiaCompletedNCT03433521
- Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)CompletedNCT03421626
- A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AMLStatus unknownNCT03417427Phase 2
- Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic MalignanciesWithdrawnNCT03414450Phase 1
- MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)Status unknownNCT03412292Phase 1
- Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)TerminatedNCT03410407
- Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)No longer availableNCT03409081
- TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic AcidCompletedNCT03397173Phase 2
- CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic SyndromeCompletedNCT03393611Phase 1
- Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid LeukemiaCompletedNCT03389724Phase 3
- Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)CompletedNCT03388749Phase 1/2
- Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 MutationsStatus unknownNCT03381781Phase 2
- Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML PatientsTerminatedNCT03381118Phase 2
- Psychological Intervention Mobile App for Patients With AMLCompletedNCT03372291Not applicable
- QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AMLWithdrawnNCT03365661Phase 2
- A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) CancerTerminatedNCT03360006Phase 1
- DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast ExcessStatus unknownNCT03356080Phase 2
- Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience.CompletedNCT03350152
- Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid LeukemiaStatus unknownNCT03348033Phase 1/2
- Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT03347994Phase 1
- Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2CompletedNCT03338348Phase 2
- Interest of a Therapeutic Follow-up of the Cytarabine in the Acute Myeloid Leukaemia: Is There Constitutional BiomarkersStatus unknownNCT03337516Not applicable
- Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and NeutropeniaCompletedNCT03333005Phase 1
- Efficacy and Safety of Nilotinib in CML-CPCompletedNCT03332511Phase 4
- Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.CompletedNCT03311815
- NLA101 in Adults Receiving High Dose Chemotherapy for AMLTerminatedNCT03301597Phase 2
- A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction ChemotherapyCompletedNCT03298516Phase 1
- Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®Status unknownNCT03287128
- Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life ConditionActive, not recruitingNCT03284593
- Cd11b and Cd56 as Prognostic Markers in Acute Myeloid LeukemiaStatus unknownNCT03283228
- Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
- Effect of Pharmacogenetics on Imatinib Plasma Level and ResponseCompletedNCT03262974
- Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 StudyStatus unknownNCT03260101
- A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years OldStatus unknownNCT03257241Phase 3
- Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCTStatus unknownNCT03256071Phase 2/3
- Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 MutationApproved for marketingNCT03245424
- The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous LeukaemiaStatus unknownNCT03241199Phase 2
- Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4logStatus unknownNCT03239886Not applicable
- Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic SyndromesStatus unknownNCT03235973Phase 1